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Summary 
The frequencies of human T cell lymphotropic virus type 1 (HTLV-1)-speciflc CD8 + precursor 
cytotoxic T lymphocytes (pCTL) were quantitated from lymphocytes obtained from the peripheral 
blood and cerebrospinal fluid (CSF) of infected individuals with and without HTLV-l-associated 
neurological disease. An estimate of the pCTL was obtained by separating CD8 + cells, plating 
these cells in limiting dilution, and testing weUs for HTLV-1 specific lysis. Targets consisted 
of autologous lymphoblastoid cell lines (LCL) infected with vaccinia  constructs expressing HTLV-1 
gene products or LCL pulsed with HTLV-1 synthetic peptides. In patients with HTLV-l-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP), the frequency of HTLV-1 p40X-specific 
pCTL was at least 40-280-fold higher than in asymptomatic HTLV-l-infected individuals. All 
HAM/TSP patients  (five of five) predominantly recognized HTLV-1 products encoded within 
the pX region. Lower pCTL to env were demonstrated in three patients,  and only one of five 
HAM/TSP patients  had pCTL to gag.  A  synthetic peptide corresponding to the tax region 
of HTLV-1 (peptide  11-19, amino acid sequence LLFGYPVYV) was recognized in association 
with human histocompatibility leukocyte antigen (HLA)-A2 in two HLA-A2 HAM/TSP patients 
with a high CD8 + pCTL frequency of 1/325  and 1/265,  respectively. A  second immuno- 
dominant region of HTLV-1 tax (peptide 90-55, amino acid sequence VPYKtLIEEL) was identified 
to be restricted by HLA-B14 in two HLA-B14 HAM/TSP patients  with a CD8 + pCTL fre- 
quency of 1/640 and 1/1,125, respectively.  Lymphocytes from the CSF of a patient with HAM/TSP 
also showed a pCTL frequency against p40X of similar magnitude to that demonstrated from 
peripheral blood lymphocytes (PBL). The HLA-A2-mediated CSF pCTL activity to the immu- 
nodominant tax-specific peptide 11-19 was also comparable to pCTL from PBL. These results 
indicate that an extremely high pCTL frequency to HTLV-1 tax-encoded peptides may be related 
to pathogenesis  of myeloneuropathy associated with HTLV-1. 
T 
he human T cell lymphotropic virus type I (HTLV-1) 1 
is closely associated with a slowly progressive neurologic 
disease called HTLV-l-associated mydopathy/tropical spastic 
paraparesis  (HAM/TSP)  (1-3).  Perivascular  mononuclear 
inftltrates in the central nervous system (CNS) of HAM/TSP 
patients and the presence of proviral DNA in spinal cord and 
medulla have been reported and strongly indicate a retrovirus- 
induced inflammatory process (4). However, the pathomech- 
1 Abbreviations used in thispager: ATL, adult T cell leukemia; CNS, central 
nervous  system;  CSF,  cerebrospinal  fluid;  pCTL,  precursor  CTL; 
HAM/TSP, HTLV-l-associated myelopathy/tropical spastic paraparesis; 
HTLV-1, human T cell lymphotropic virus type 1; LCL, lymphoblastoid 
cell line;  MRI, magnetic resonance  imaging. 
anism of this demyelinating myeloneuropathy is still not un- 
derstood. 
The vast majority of individuals infected by HTLV-1 re- 
main asymptomatic,  and <5%  develop clinical disease in- 
cluding either HAM/TSP or the neoplastic disorder, adult 
T cell leukemia (ATL). These different outcomes of an HTLV-1 
infection may be explained by the existence of different viral 
strains (5, 6), by genetic predisposition  (7), or by differences 
in host-immune response (8, 9). Thus far, however, no unique 
sequence has been associated with any disease (10) or asymp- 
tomatic carrier state, and an association of a "disease suscep- 
tibility" allele is unclear. 
The presence of HTLV-l-specific CTLs in the peripheral 
blood of HAM/TSP patients has been suggested as one ex- 
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tent with this hypothesis is the observation in HIV-1 infec- 
tion, that retrovirus-specific  CTL have been shown to have 
deleterious effects especially, in the CNS and lungs (12-14). 
Preliminary data on HTLV-l-specific precursor frequen- 
cies of CTL (pCTL) from peripheral blood of two patients 
with HAM/TSP indicate that the number of such cells is 
extraordinarily high (15). These observations suggest that 
HTLV-1 induces a strong T lymphocyte immune response, 
and that the CTL precursor pool may be amplified by the 
chronic nature of the infection. Also, the amounts of pX and 
probably env DNA were found to be greater in the CNS 
tissue from HAM/TSP patients than in brain tissue from pa- 
tients with ATL (4) which indicates increased viral load in 
HTLV-l-associated neurological disease. 
In this report, limiting dilution analysis of lymphocytes 
from both peripheral blood and cerebrospinal  fluid (CSF) of 
patients with HAM/TSP and asymptomatic HTLV-l-infected 
individuals has been performed in order to quantitate the fre- 
quencies  of HTLV-l-specific  CD8 +  pCTL.  Both  virus- 
specific pCTL as well as HLA-restricted peptide-specific pCTL 
responses were determined. The data extend our previous ob- 
servations which demonstrated high CTL activity to the tax 
region of HTLV-1 in HAM/TSP patients, and serve further 
to increase our understanding of the role that these CTLs 
play in the pathogenesis of neurological HTLV-1 infection. 
MA) at final concentrations of 100, 50, 25, 12.5, 6, and 3 cells 
per well in 0.2 ml of media containing KPMI 1640 (Whittaker 
Bioproducts, Walkersville,  MD) plus 10% FCS (Gibco, Grand Is- 
land, NY). Irradiated (5,000 rad) allogeneic feeders from HTLV-1 
seronegative donors were prestimulated  with PHA (GIBCO BRL, 
Gaithersburg, MD) at a final concentration of 1 #g/well for 30 
min at 37~  and added to each well at a concentration of 1.0  x 
10  s cells/well in RPMI 1640 media containing 10% FCS. 24 h 
later, 100/~1 of supematant from each well was removed  and replaced 
with 100/xl of fresh media containing RPMI 1640 plus 10% FCS, 
10% purified IL-2 (Cellular Products, Inc., Buffalo, NY), and 100 
U/ml of  rlL-2 (Cetus Corp., Emeryville,  CA). All wells were refed 
two times per week with IL-2 containing media. After 2-3 wk, 
cell buttons became  prominent, and lines derived  from this cloning 
were screened for cytotoxicity against SlCr-labeled  autologous LCL 
infected with the HTLV-1 vacdnia-p40x, gag, env, or vaccinia-HA 
constructs, or pulsed with 10/~g/ml of peptides tax 11-19 (amino 
acid sequence LLFGYPVYV), or tax 90-55 (VPYKR/EEL). 
CSF Lymphocytes.  Lymphocytes  were obtained from CSF by 
atraumatic lumbar puncture in which <1 RBC/mm  3 was present. 
As the number of cells was insufficient  for CD8 + sorting by flow 
cytometry analysis,  unfractioned cells were cloned in limiting dilu- 
tion and cultured as described above. 
Peptides 
Peptides were synthesized  using a stepwise solid-phase  approach 
on a peptide synthesizer (model 430A; Applied Biosystems, Inc., 
Foster City, CA) at Medimmune Inc. (16). 
Materials  and Methods 
Subjects 
The clinical characteristics of patients with HAM/TSP and 
asymptomatic  HTLV-l-infected  individuals  are summarized  in Table 
1. PBL were obtained from five patients with HAM/TSP or five 
HTLV-l-infected asymptomatic individuals  undergoing evaluation 
and treatment at the Clinical Center at the National Institutes of 
Health (NIH) (see Table 1). Four patients (Nos. 1-4) had a slowly 
progressive spastic paraparesis, and patient No. 5 (spouse of pa- 
tient No. 4) had hyperreflexia  in the lower extremities and extensor 
plantar responses indicative  of  corticospinal tract lesion(s). Subject 
No. 6 was an asymptomatic spouse of patient No. 1, and the re- 
maining subjects (Nos. 7-10) were clinically asymptomatic. All 
HAM/TSP patients were HTLV-1 seropositive  in serum and CSF. 
The CSF of all but one patient (No. 5) showed mild pleocytosis, 
elevated IgG levels, and/or the presence of  oligoclonal bands. Mag- 
netic resonance imaging (MRI) of three patients with HAM/TSP 
(Nos. 1-3) showed spinal cord shrinkage in the cervical or thoracic 
region. MR/of  patient No. 4 was normal. No MILl data was avail- 
able on patient No. 5. HAM/TSP patient No. 4 became infected 
with HTLV-1 through hemotransfusion.  Histocompatibility  typing 
was performed on PBL or EBV-transformed  lymphoblastoid cell 
lines (LCL) by the Tissue Typing Laboratory at the NIH Clinical 
Center. 
Cloning of Lymphocytes in Limiting Dilution 
PBL.  PBL isolated  on Hcoll-sodium metrizoate  gradients (lym- 
phocyte separation  media [LSM];  Organon Teknika, Rockville,  MD) 
were CD8 + sorted (>98%  purity)  by flow cytometry analysis 
(Epics, Coulter Corp., Hialeah, FL) and cloned in limiting dilu- 
tion in 96-well  plates (catalog  No. 3799; Costar Corp., Cambridge, 
Initial Screening of CTL Clones by CTL Assay 
As targets, 2 x  106 autologous EBV-transformed  I.CL were in- 
fected  with various HTLV-1 vaccinia  recombinants  as described  pre- 
viously (11) at a multiplicity of infection of 10.0 for 10-14 h and 
then  incubated with 0.2  mCi  of Na&Cr  (Amersham Corp., 
Arlington Heights, IL) for 1.5 h. Target cells infected with the 
vaccinia-p40x expressed p40x (tax) and p21x; vaccinia-gag  expressed 
p19, p24, and p15 internal structural  proteins; vaccinia-env  expressed 
gp62, gp46, and gp21 surface  glycoprotein;  and control vaccinia-HA 
expressed no HTVD1 proteins. For initial screening, target cells 
plated at a final concentration of 3.5  x  103 cells/well were in- 
cubated with 20 #l/well of PBL or CSF effector cells in culture 
media for 4 h at 37~  in 5% CO2. 
Percent specific lysis was calculated by the following formula: 
100  x [(test  cpm -  spontaneous cpm)/(maximal cpm -  sponta- 
neous cpm)]. 
Precursor frequency analyses  were determined by cloning cells 
in limiting dilution and testing wells for HTLV-1 specific  lysis of 
autologous LCL infected with the HTLV-1 or vaccinia-HA con- 
trol recombinants, HTLV-1 peptides, or irrelevant peptides. In- 
dividual wells demonstrating >25% specific  lysis were screened as 
positive after subtraction of vaccinia-HA control. 
Linear regression analysis was performed on limiting dilution 
cultures. The best straight line was determined using the least 
squares method.  Results are plotted graphically (semilog plots) 
where the y-axis represents the negative natural logarithm of the 
fraction of nonresponding cultures and the x-axis represents the 
cell input (17). Experimental points fitting a straight line allow 
an estimate of the frequency of precursor cells because by inter- 
polating at the level of 37% nonresponding cultures, the size of 
the sample containing an average of one precursor cell can be esti- 
mated (17). 95% confidence  limits were calculated  based upon true 
mean value of the dependent variable (cell input). Wells displaying 
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for the total CSF or PBL population was calculated as the per- 
centage of CD8 + cells times the precursor frequency  of the CD8 + 
population. 
Results 
HTLV-I  p4OX-specific pCTL  Frequencies from  PBL  in 
HTLV-I Seropositive  Individuals with and without HAM/TSP. 
An estimate of  the pCTL frequency was obtained by separating 
CD8 + cells and plating these cells in limiting dilution. The 
HTLV-l-specific pCTL frequencies of patients with HAM/ 
TSP and asymptomatic HTLV-1 seropositive subjects are sum- 
marized in Table 2, and representative plots for p40X specific 
lysis are shown in Fig. 1. The results show that all HAM/TSP 
patients had high HTLV-l-specific pCTL and that the fre- 
quencies of HTLV-1 p40X-specific CD8 + pCTL from pe- 
ripheral blood ranged between 1/75 and 1/320. In contrast, 
CD8 + pCTL specific for HTLV-1 p40X were only detected 
in three of five asymptomatic HTLV-l-infected individuals 
and frequencies ranged between 1/2,900 and 1/20,850.  These 
pCTL frequencies were 40-280-fold lower than in HAM/TSP 
patients (Fig.  1 and Table 2). A comparison of the number 
of HTLV-1 p40X-spedfic clones between asymptomatic No. 
6 and HAM/TSP patient No. 1 is shown in Table 3. In two 
asymptomatic individuals, pCTL were too low to be de- 
termined. 
pCTL Frequencies  to Different Regions of  HTLV-1.  For es- 
timating pCTL frequencies to various HTLV-1 proteins, the 
frequency of cells lysing autologous B cells infected with vac- 
Table  1.  Characteristics  of HTLV-l-infected Patients with and without HAM/TSP 
HLA type 
Patient No./  Country of  Age in yr/  Duration  of 
Clinical status  origin  sex  disease  A  B  C  DR  DQw 
yt" 
1.  HAM/TSP  USA  51/M  14  2,28  18,44  6,7  5,7  2,3 
2.  HAM/TSP  Panama  31/F  7  11,24  7,14  1,7  2,5 
3.  HAM/TSP  Jamaica  45/F  8  28,32  14,70  3  1,7  1,2 
4.  HAM/TSP  USA  68/M  2  1,3  7,62  3  2,4  6,7 
5.  Corticospinal tract lesion  USA  70/F  1  1,2  37,60  3,6  11,15  6,7 
6.  Asymptomatic  Japan  46/F  11,31  54,60  1,3  4,9  3 
7.  Asymptomatic  Barbados  46/F  28,31  60,63  3  4,18  4,7 
8.  Asymptomatic  USA  43/F  2  53,  4 
9.  Asymptomatic  Jamaica  39/F  2,30  43,43,  3,15  4,6 
10.  Asymptomatic  Jamaica  29/F  Not available 
Table  2.  HTLV-1-specific  pCTL Frequencies  of CD8 + Cells  from 10 HTLV-1-infected Subjects with and without HAM/TSP 
Patient No./Clinical status  p40X  Env  Gag 
1.  HAM/TSP  1/300  (1/228-372)  1/8140  (1/4,264-12,016)  1/4,337  (1/2,204-6,470) 
2.  HAM/TSP  1/265  (1/205-325)  1/4300 (1/2,497-6,103)  * 
3.  HAM/TSP  1/320  (1/270-370)  *  * 
4.  HAM/TSP  1/75  (1/20-130)  1/1590 (1/793-2,387)  * 
5.  HAM/TSP  1/186  (1/107-265)  *  Not available 
6.  Asymptomatic  1/2,900  (1/1,600-4,200)  *  * 
7.  Asymptomatic  1/3,620  (1/1,816-5,424)  *  * 
8.  Asymptomatic  *  *  * 
9.  Asymptomatic  1/20,850  (1/10,802-30,898)  *  * 
10.  Asymptomatic  *  *  * 
* Too low to be determined. Of 360 wells screened for lysis on the respective targets, no well demonstrated  any specific cytotoxicity.  Values in 
parentheses represent 95% confidence  limits of the calculated frequencies. 
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Figure 1.  Quantitation of HTLV-1 
p40X-specific  CD8 +  precursor 
CTL  frequencies.  Precursor  fre- 
quency analyses  were performed on 
freshly isolated, sorted, and in lim- 
iting dilution-cloned  PBL from pa- 
tients with HAM/TSP (A-D) or 
asymptomatic HTLV-1 infection (E) 
as described in the Materials and 
Methods section. Targets were Cr- 
labeled  autologous  LCL  infected 
with  the HTLV-1 vaccinia-p40X 
constructs. Effector cell frequencies 
were extrapolated as reciprocal of 
x  variable  where y  equals  0.37. 
Individual  wells  demonstrating 
>25% specific lysis were screened 
as positive. 
cinia constructs that expressed dif[erent HTLV-1 gene prod- 
ucts were determined. Table 2 shows that in HAM/TSP, the 
frequencies  of HTLV-1 p40X-specific CD8 + pCTL from 
peripheral blood were extremely high. However,  some pa- 
Table  3.  Cloning of CD8 + HTLV-1-specific CTL from 
Lymphocytes in the Peripheral Blood  from Patients with HAM/TSP 
and Asymptomatic HTLV-I  Carriers (ASX) 
Number of positive wells/60 wells tested 
Cells/well 
p40X  Env  Gag 
HAM/TSP  ASX  HAM/TSP  HAM/TSP 
Patient  Patient  Patient  Patient 
No.  1  No.  6  No.  4  No.  1 
100  24  2  ND  2 
50  19  2  2  2 
25  16  1  1  0 
12.5  11  0  1  1 
6  9  1  0  0 
3  8  0  0  1 
Precursor  1/310  1/2,900  1/1,590  1/4,340 
frequency 
tients at the dilutions tested also showed some reactivity to 
HTLV-1 env (Nos.  1, 2,  and 4) and HTLV-1 gag (No.  1) 
(Table 3), and estimates of pCTL to those regions are given 
in Table 2. In all cases, the pCTL to the p40X region were 
significantly greater than those to env and gag. 
Although the magnitude of HTLV-l-specific pCTL re- 
sponse (i.e., frequencies of specific pCTL) in asymptomatic 
HTLV-l-infected individuals were markedly lower than in 
patients with HTLV-l-related neurologic disease, the recog- 
nition of viral products encoded within the pX region still 
predominated. The frequencies of gag- and env-specific  pCTL 
were too low to be estimated. Of the 360 wells screened for 
lysis on the respective targets, no well demonstrated any specific 
cytotoxicity. This indicated that in HTLV-1 asymptomatic 
carriers,  if lysis could be detected, all the HTLV-l-specific 
pCTL responses were directed against pX gene products and 
these responses were significantly lower than in HAM/TSP 
patients. 
Precursor Frequencies of HTLV-I Peptide-specific CTL.  The 
fine peptide specificity of the CD8 + pCTL to the HTLV-1 
p40X regions was determined. Previous studies had demon- 
strated that HTLV-1 tax synthetic peptides, tax 11-19, and 
tax 90-55 were recognized in the context of HLA-A2 and 
B14, respectively (18). The results in Fig. 2, B and F show 
that a high frequency of purified CD8 + cloned lymphocytes 
from the peripheral blood of HLA-A2 HAM/TSP patients 
Nos. 1 and 5 recognized HTLV-1 tax peptide 11-19. The fre- 
quency of tax peptide 11-19-specific  pCTL was of similar mag- 
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Figure  2.  Quantitation  of HTLV-l-specific CD8 + precursor CTL fre- 
quencies with HLA-A2 and HLA-B14 restriction of HTLV-1 peptides. An 
estimate of the pCTL was obtained  and calculated as in Fig. 1. Targets 
were Crqabeled  autologous LCL infected with HTLV-1 p40x (.4, C, and 
E) or pulsed with peptides  tax  11-19 (FGYPV) (B and F) or tax 90-55 
(VPVKI~IEEL) (D). 
nitude to that of 1MOX-slxcific pCTL (Fig. 2, A andE). There- 
fore, such high precursor frequencies to this peptide indicate 
that major responses within 1MOX in these subjects are directed 
towards tax peptide 11-19. In addition, Fig. 2 D demonstrates 
that the sorted and subsequently cloned CD8 + lymphocytes 
from the peripheral blood of HLA-B14 patient No.  3 had 
a high CD8 + pCTL frequency  to tax peptide 90-55.  The 
second HLA-B14 HAM/TSP patient  No. 2 had a tax pep- 
tide  90-55-specific  pCTL  frequency  of 1/1,125  (data not 
shown). These data indicate that the predominant response 
within p40X against tax peptide 90-55 is restricted by HLA- 
B14.  Expansion of these clones and subsequent CTL assays 
confirmed the specificities  of these responses. 
HTLV-I  pCTL  Frequencies in  CSE  Because  of  low 
numbers of CSF leukocytes in patient No. 1, these cells were 
unable to be sorted into CD8 + T cells, and, therefore, they 
were directly cloned in limiting dilution. It is interesting that 
an initial screening  of those CSF lymphocytes showed that 
there was a high pCTL frequency (1/145) against p40x (Fig. 
3 A) which was of a similar magnitude (1/300)  to that in 
PBL (Fig. 1 A and Table 2). Env pCTL could also be demon- 
strated (Fig. 3 B). The pCTL of these CSF lymphocytes from 
that HLA-A2 HAM/TSP patient were shown to be reactive 
against  tax peptide 11-19, which was similar in magnitude 
to that in corresponding peripheral blood (Figs. 2 B and 3 C). 
Discussion 
The present  data indicate  that  HTLV-l-specific  CD8 + 
pCTL frequencies from lymphocytes obtained from the pe- 
ripheral blood and CSF of patients with HAM/TSP are ex- 
tremely high, whereas the magnitude of pCTL reactivity from 
subjects with asymptomatic HTLV-1 infection is clearly lower 
or absent. These pCTL predominantly recognized HTLV-1 
products encoded within the pX region.  In addition, we 
confirmed that the recognition of HTLV-1 tax epitopes  11- 
19 (LLFGYPVYV) and 90-55 (VPYKRIEEL) within the tax 
region of HTLV-1 is restricted by HLA-A2 and HLA-B14, 
respectively  (18). 
The presence of circulating HTLV-l-specific CTL in pa- 
A 
I/I 
z 
0 
a. 
uJ  n- 
M~ 
Z 
Z 
9 
I- 
0 
< 
Patient  #1  a  1 
CTL=1/145 
￿9  ,  ￿9  ,  .  ,  .  ,  ￿9  ,  .  , 
40  8D  120  160  200  240 
#  OF  CELLS 
1  Patient  #1  C 
40  80  120  160  200  240  280 
#  OF  CELLS 
Patient  #1 
pCTL:1~3s 
￿9  ,  -  w  -  ,  -  ,  ,  ,  -  ,  ,  ,  - 
40  80  120  160  200  240  280 
#  OF  CELLS 
Figure  3.  Quantitation of HTLV- 
1-specific pCTL f~uencies in CSF. 
Lymphocytes  were obtained  from 
CSF by atraumatic lumbar puncture 
and  cloned  in  limiting  dilution. 
Targets were Cr-labeled autologous 
LCL infected  with HTLV-1 p40x 
(.4), env (/3), or pulsed with tax pep 
tide 11-19 (C).  Vaccinia-HA con- 
structs  were  used  as  controls. 
Effector  cell frequencies  were ex- 
trapolated as in Fig. 1. Individual 
wells demonstrating >25 % specific 
lysis were screened as positive. 
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in CD8 + T cells in spinal cord lesions of such patients has 
been reported (5, 11, 19, 20). Also, the HTLV-1 viral load 
in the CNS of these patients was found to be higher than 
in patients with ATL (4). Since in asymptomatic HTLV-I-in- 
fected individuals the responses of virus-specific CTL are lower 
or absent (11, 21), it may be that the high level of CTL ac- 
tivity in HAM/TSP is related to the persistence of HTLV-1 
in CNS, and/or to chronicity of this infection associated with 
an increased viral load (4). For example, in HIV-1 infection, 
another retroviral disease frequently associated with CNS in- 
fection in the later stages of AIDS, systemic and local in- 
crease of the viral load is believed to lead to HIV-l-specific 
neuropathology (22). In HTLV-1 infection, the generation 
of pCTL may have dual consequences. These cells are gener- 
ated presumably to suppress viral replication through the lysis 
of infected cells or through the production of cytokines with 
antiviral properties. In healthy HTLV-l-infected individuals 
CTL targeted to chronically infected T  cells may decrease 
viral load and maintain clinically asymptomatic infection. On 
the other hand, infection of neural or glial cells followed by 
damage of these cells by CTL or by disturbance of their func- 
tion by cytokine responses  could contribute to the patho- 
genesis of neurologic disease associated with HTLV-1. 
In HIV-1 infection, high frequencies of both HIV-specific 
CTL and pCTL have been detected even in asymptomatic 
individuals (23-25). The present results with HAM/TSP pa- 
tients, however, indicate that in this disease, pCTL frequen- 
cies are at least 40-fold higher than in infection by HIV-1. 
It is interesting that whereas late stages of HIV infection 
characterized by immunological and neurological deteriora- 
tion are accompanied by the decline of both CTL and their 
precursors, patients with neurological disease associated with 
HTLV-1 display significantly higher pCTL frequencies than 
asymptomatic carriers. This would imply that the presence 
of HTLV-l-specific CTL in HAM/TSP may be a disease- 
specific event, potentially contributing to the pathogenesis 
of this disorder. 
In HAM/TSP patients, an infiltration of CD8 + cells in 
spinal cord lesions, the presence of the HTLV-1 p19 core pro- 
tein (19), HTLV-1 genomic sequences (20), and HLA class 
I molecules in such lesions (19), support the suggestion that 
these CD8 +  cells in  HAM/TSP  spinal  cord lesions  may 
cause lysis of infected cells in thoracic cord. Alternatively, 
cytokine responses could be induced that could adversely affect 
the function of uninfected neurons and glia within the CNS 
and contribute to the pathological effects observed in patients 
with HAM/TSP.  The demonstration of HTLV-l-specific 
CD8 + CTL directly from lymphocytes obtained from the 
CSF of patients with HAM/TSP (15) is consistent with this 
hypothesis and provides an explanation for the neurological 
manifestations of this disease. The results from the present 
study demonstrating similar pCTL frequencies in the CSF 
and blood, further support the view that CTL activity may 
be essential to the pathogenesis of HAM/TSP. 
Although pCTL responses to HTLV-1 structural proteins 
were observed in some HAM/TSP patients, pCTL predomi- 
nantly recognized HTLV-1 products encoded within the pX 
region. This confirms earlier data showing that CTL obtained 
directly from the peripheral blood of HAM/TSP patients pre- 
dominantly lysed targets infected with the HTLV-1 p40x vac- 
cinia constructs (9, 11). This indicates that a product of the 
HTLV-1 tax gene is recognized by both pCTL and CTL ob- 
tained directly from peripheral blood. Other HTLV-1 an- 
tigens, such as env or gag proteins, can also be recognized, 
but these responses occur with a lower frequency than the 
responses  to the tax region of HTLV-1. 
The observation that in HAM/TSP, pCTL from HLA- 
A2 patients and HLA-B14 patients, respectively, recognized 
tax peptide 11-19 and 90-55, indicates that small peptides of 
the HTLV-1 tax region can be recognized by specific pCTL 
in association with these HLA class I alleles. Therefore, HTLV- 
1-specific pCTL responses to the tax protein are not restricted 
to a particular haplotype, but rather to immunodominant 
peptide fragments that are associated with particular HLA 
alleles. HLA-restricted CTL to the tax protein have been found 
in association with HLA-A2, A3, and B14 (18). Moreover, 
since a strong CTL response to tax in HAM/TSP patients 
is related to a single immunogenic  region in individuals with 
a given haplotype, this may be useful in developing strategies 
to interfere with peptide/HLA binding (26). 
If HTLV-1-specific CTL play a central role in the develop- 
ment of HAM/TSP, then immunotherapeutic strategies that 
focus on eliminating these cells or inhibiting their activity, 
could be clinically significant. The information obtained from 
immunotherapy of neurological HTLV-1 infection, could be 
extended to other CNS diseases of retroviral origin, such as 
CNS infection by HIV-1,  and possibly to other chronic- 
progressive neurological diseases such as multiple sclerosis. 
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